Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Upstream Bio (UPB) EBIT (2023 - 2025)

Historic EBIT for Upstream Bio (UPB) over the last 3 years, with Q3 2025 value amounting to -$37.8 million.

  • Upstream Bio's EBIT fell 10025.41% to -$37.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$140.5 million, marking a year-over-year decrease of 11362.2%. This contributed to the annual value of -$77.8 million for FY2024, which is 9385.75% down from last year.
  • Latest data reveals that Upstream Bio reported EBIT of -$37.8 million as of Q3 2025, which was down 10025.41% from -$44.3 million recorded in Q2 2025.
  • Upstream Bio's EBIT's 5-year high stood at -$9.4 million during Q3 2023, with a 5-year trough of -$44.3 million in Q2 2025.
  • For the 3-year period, Upstream Bio's EBIT averaged around -$24.0 million, with its median value being -$18.9 million (2024).
  • As far as peak fluctuations go, Upstream Bio's EBIT crashed by 8365.67% in 2024, and later crashed by 15283.35% in 2025.
  • Upstream Bio's EBIT (Quarter) stood at -$14.3 million in 2023, then crashed by 83.66% to -$26.3 million in 2024, then tumbled by 43.76% to -$37.8 million in 2025.
  • Its EBIT stands at -$37.8 million for Q3 2025, versus -$44.3 million for Q2 2025 and -$32.0 million for Q1 2025.